Literature DB >> 2838553

Epidermodysplasia verruciformis in a patient with Hodgkin's disease: characterization of a new papillomavirus type and interferon treatment.

G Gross1, K Ellinger, A Roussaki, P G Fuchs, H H Peter, H Pfister.   

Abstract

A new human papillomavirus (HPV) was discovered in disseminated, macular, pityriasis versicolor-like lesions on the skin of the neck, face, scalp, and pubic region of a 42-year-old male suffering from Hodgkin's disease. Histopathology revealed features characteristic of epidermodysplasia verruciformis (ev). In contrast to classical ev, the lesions were almost exclusively seen in previously irradiated and UV-exposed skin areas. Papillomavirus capsid antigen was demonstrated with the genus-specific antiserum and the patient's serum, which had IgM and IgG antibody titers. HPV DNA was isolated from biopsies and cloned into the vector pIC20H. It proved to be related to ev-associated viruses, showing 23% cross-hybridization with DNA of the closest relative HPV14. The new HPV type was named HPV46. The genome was physically mapped and colinearly aligned with HPV8 DNA to establish its gene organization. Interferon treatment of the patient did not significantly change the clinical picture nor was the concentration of viral DNA per lesion affected. However, no virus capsid antigen was detectable after starting treatment.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2838553     DOI: 10.1111/1523-1747.ep12463287

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  9 in total

1.  Risk factors for non-initiation of the human papillomavirus vaccine among adolescent survivors of childhood cancer.

Authors:  James L Klosky; Kathryn M Russell; Kristin E Canavera; Heather L Gammel; Jason R Hodges; Rebecca H Foster; Gilbert R Parra; Jessica L Simmons; Daniel M Green; Melissa M Hudson
Journal:  Cancer Prev Res (Phila)       Date:  2013-08-27

Review 2.  Heterogeneity of the human papillomavirus group.

Authors:  E M de Villiers
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

Review 3.  Epidermodysplasia verruciformis in an HIV-infected man: a case report and review of the literature.

Authors:  Amit Kaushal; Shane Silver; Ken Kasper; Alberto Severini; Sate Hamza; Yoav Keynan
Journal:  Top Antivir Med       Date:  2012-12

4.  Prevalence of antibodies to human papillomavirus type 8 in human sera.

Authors:  G Steger; M Olszewsky; E Stockfleth; H Pfister
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

5.  Autosomal dominant epidermodysplasia verruciformis lacking a known EVER1 or EVER2 mutation.

Authors:  David F McDermott; Bryan Gammon; Peter J Snijders; Ihunanya Mbata; Beth Phifer; A Howland Hartley; Chyi-Chia Richard Lee; Philip M Murphy; Sam T Hwang
Journal:  Pediatr Dermatol       Date:  2009 May-Jun       Impact factor: 1.588

Review 6.  Human papillomavirus vaccination in survivors of childhood cancer.

Authors:  James L Klosky; Heather L Gamble; Sheri L Spunt; Mary E Randolph; Daniel M Green; Melissa M Hudson
Journal:  Cancer       Date:  2009-12-15       Impact factor: 6.860

Review 7.  Multiple metachronous skin squamous cell carcinomas and epidermodysplasia verruciformis in the head region: a human papilloma virus-associated disease.

Authors:  B P Weber; G Fierlbeck; H G Kempf
Journal:  Eur Arch Otorhinolaryngol       Date:  1994       Impact factor: 2.503

8.  Acquired epidermodysplasia verruciformis in a renal transplant recipient--case report.

Authors:  Alena Darwich Mendes; Maraya de Jesus Semblano Bittencourt; Emanuella Rosyane Duarte Moure; Camila Maria D'Macêdo; Igor Nagai Yamaki; Dyandra Moreira de Araújo
Journal:  An Bras Dermatol       Date:  2014 Jan-Feb       Impact factor: 1.896

9.  Inherited MST1 deficiency underlies susceptibility to EV-HPV infections.

Authors:  Amandine Crequer; Capucine Picard; Etienne Patin; Aurelia D'Amico; Avinash Abhyankar; Martine Munzer; Marianne Debré; Shen-Ying Zhang; Geneviève de Saint-Basile; Alain Fischer; Laurent Abel; Gérard Orth; Jean-Laurent Casanova; Emmanuelle Jouanguy
Journal:  PLoS One       Date:  2012-08-27       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.